{"id":300,"date":"2026-10-01T00:07:02","date_gmt":"2026-09-30T23:07:02","guid":{"rendered":"https:\/\/novameds.health\/ca\/glp-1-muscle-loss\/"},"modified":"2026-10-01T09:06:20","modified_gmt":"2026-10-01T13:06:20","slug":"glp-1-muscle-loss","status":"publish","type":"post","link":"https:\/\/novameds.health\/ca\/knowledge-hub\/glp-1-muscle-loss\/","title":{"rendered":"GLP-1 Medications and Muscle Mass: Preserving Lean Tissue During Weight Loss"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\">Rapid, substantial weight loss achieved with GLP-1 receptor agonists (semaglutide) and dual GIP\/GLP-1 agonists (tirzepatide) has brought heightened scrutiny to body composition changes. Specifically, clinicians and patients are concerned with <strong>lean body mass loss<\/strong> and the potential development of <strong>sarcopenic obesity<\/strong>\u2014a state characterized by low skeletal muscle mass and strength relative to remaining body weight.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Any substantial caloric deficit, whether induced by lifestyle, bariatric surgery, or pharmacotherapy, inevitably results in the loss of both adipose tissue and fat-free mass (which includes skeletal muscle, water, connective tissue, and organ mass). However, the critical clinical question is whether GLP-1 medications cause <em>disproportionate<\/em> muscle wasting, and what evidence-based interventions can mitigate this effect.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">This guide reviews dual-energy X-ray absorptiometry (DEXA) sub-study findings from landmark clinical trials, the biological drivers of muscle breakdown, and actionable strategies to preserve functional muscle mass.<\/p>\n\n\n\n<aside class=\"wp-block-group nm-takeaways is-layout-flow wp-block-group-is-layout-flow\">\n<h2 class=\"wp-block-heading\">Key takeaways<\/h2>\n\n\n\n<ul class=\"wp-block-list\"><li><strong>Expected Physiological Ratio:<\/strong> In the STEP-1 and SURMOUNT-1 body composition sub-studies, lean mass accounted for approximately <strong>25% to 40% of total weight lost<\/strong>, which aligns closely with historical data from lifestyle-induced caloric deficits and bariatric surgery.<\/li><li><strong>Improved Lean-to-Fat Ratio:<\/strong> Because fat mass decreased by a greater absolute percentage than lean mass, the overall <strong>percentage of lean body mass increased<\/strong> relative to total weight.<\/li><li><strong>Sarcopenia Risks in Older Adults:<\/strong> In patients aged 65 and older, or individuals with pre-existing frailty, losing skeletal muscle can impair physical mobility, elevate fall risk, and depress baseline functional independence.<\/li><li><strong>Protein Synthesis Deficits:<\/strong> Severe appetite suppression frequently causes involuntary protein under-consumption (&lt;0.8 g\/kg\/day), accelerating muscle protein catabolism during weight loss.<\/li><li><strong>Preservation Triad:<\/strong> Combining progressive resistance exercise (2 to 4 sessions weekly), elevated dietary protein intake (1.2 to 1.6 g\/kg\/day), and avoiding overly aggressive caloric deficits preserves muscle protein synthesis and functional strength.<\/li><\/ul>\n<\/aside>\n\n\n\n<nav class=\"wp-block-group nm-toc is-layout-flow wp-block-group-is-layout-flow\" aria-label=\"Contents\">\n<h2 class=\"wp-block-heading\">Contents<\/h2>\n\n\n\n<ol><li><a href=\"#understanding-lean-mass-vs-skeletal-muscle\">Understanding Lean Mass vs Skeletal Muscle<\/a><\/li><li><a href=\"#what-clinical-trial-dexa-scans-reveal\">What Clinical Trial DEXA Scans Reveal<\/a><\/li><li><a href=\"#is-incretin-induced-muscle-loss-unique\">Is Incretin-Induced Muscle Loss Unique?<\/a><\/li><li><a href=\"#risks-sarcopenic-obesity-and-metabolic-consequences\">Risks: Sarcopenic Obesity and Metabolic Consequences<\/a><\/li><li><a href=\"#nutritional-strategies-protein-timing-and-leucine-thresholds\">Nutritional Strategies: Protein Timing and Leucine Thresholds<\/a><\/li><li><a href=\"#exercise-protocols-resistance-training-vs-aerobic-exercise\">Exercise Protocols: Resistance Training vs Aerobic Exercise<\/a><\/li><li><a href=\"#clinical-monitoring-dexa-scans-and-handgrip-dynamometry\">Clinical Monitoring: DEXA Scans and Handgrip Dynamometry<\/a><\/li><li><a href=\"#frequently-asked-questions\">Frequently Asked Questions<\/a><\/li><li><a href=\"#references\">Scientific references<\/a><\/li><\/ol>\n<\/nav>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"understanding-lean-mass-vs-skeletal-muscle\">Understanding Lean Mass vs Skeletal Muscle<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">When evaluating body composition data from clinical trials, distinguishing between &#8220;fat-free mass&#8221; (lean mass) and &#8220;skeletal muscle&#8221; is crucial:<\/p>\n\n\n\n<ul class=\"wp-block-list\"><li><strong>Fat-Free Mass (FFM \/ Lean Mass):<\/strong> Includes all non-adipose tissues: skeletal muscle, cardiac and smooth muscle, bone mineral content, visceral organs (liver, kidneys), intra- and extracellular water, and blood volume.<\/li><li><strong>Skeletal Muscle Mass:<\/strong> The voluntary contractile muscle tissue attached to bones. Skeletal muscle typically comprises only 40% to 50% of total fat-free mass.<\/li><\/ul>\n\n\n\n<pre class=\"wp-block-preformatted nm-diagram\">Total Body Weight\n\u251c\u2500\u2500 Fat Mass (Subcutaneous &amp; Visceral Adipose)\n\u2514\u2500\u2500 Fat-Free Mass (Lean Mass)\n    \u251c\u2500\u2500 Skeletal Muscle (~45% of Lean Mass)\n    \u251c\u2500\u2500 Water (Intra- &amp; Extracellular) (~40% of Lean Mass)\n    \u251c\u2500\u2500 Visceral Organs (~10% of Lean Mass)\n    \u2514\u2500\u2500 Bone Mineral &amp; Connective Tissue (~5% of Lean Mass)<\/pre>\n\n\n\n<p class=\"wp-block-paragraph\"><em>Key Insight:<\/em> A significant portion of &#8220;lean mass&#8221; lost during rapid weight loss is simply intracellular water and structural supportive tissue that is no longer required to support a heavier frame, rather than purely functional skeletal muscle breakdown.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"what-clinical-trial-dexa-scans-reveal\">What Clinical Trial DEXA Scans Reveal<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">Body composition was directly measured using dual-energy X-ray absorptiometry (DEXA) in pre-specified sub-studies of the pivotal phase 3 trials:<\/p>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"1-semaglutide-24-mg-the-step-1-dexa-sub-study\">1. Semaglutide 2.4 mg: The STEP-1 DEXA Sub-study<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">In a sub-study of 140 participants evaluated with DEXA over 68 weeks:<\/p>\n\n\n\n<ul class=\"wp-block-list\"><li><strong>Total Fat Mass Reduction:<\/strong> Decreased by an average of <strong>-19.3%<\/strong> (-8.36 kg).<\/li><li><strong>Total Lean Mass Reduction:<\/strong> Decreased by an average of <strong>-9.7%<\/strong> (-5.26 kg).<\/li><li><strong>Composition of Weight Lost:<\/strong> Fat mass accounted for <strong>61.4%<\/strong> of the weight lost, while lean mass accounted for <strong>38.6%<\/strong>.<\/li><li><strong>Proportion of Lean Mass:<\/strong> Because fat mass decreased far more than lean mass, the ratio of lean body mass to total body weight actually <strong>increased by 3.0 percentage points<\/strong> (from 60.5% at baseline to 63.5% at week 68). Visceral fat declined by 33%.<\/li><\/ul>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"2-tirzepatide-15-mg-the-surmount-1-dexa-sub-study\">2. Tirzepatide 15 mg: The SURMOUNT-1 DEXA Sub-study<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">In a sub-study of 160 participants assessed over 72 weeks:<\/p>\n\n\n\n<ul class=\"wp-block-list\"><li><strong>Total Fat Mass Reduction:<\/strong> Decreased by an average of <strong>-33.9%<\/strong>.<\/li><li><strong>Total Lean Mass Reduction:<\/strong> Decreased by an average of <strong>-10.9%<\/strong>.<\/li><li><strong>Composition of Weight Lost:<\/strong> Fat mass represented approximately <strong>74%<\/strong> of total weight loss, while lean mass represented <strong>26%<\/strong>.<\/li><li><strong>Lean-to-Fat Ratio:<\/strong> The ratio of lean mass to fat mass improved from 1.7 at baseline to 2.4 at week 72.<\/li><\/ul>\n\n\n\n<figure class=\"wp-block-table nm-table\"><table><thead><tr><th>Trial &amp; Molecule<\/th><th>Total Weight Lost<\/th><th>Fat Mass Lost<\/th><th>Lean Mass Lost<\/th><th>% of Loss as Lean Mass<\/th><\/tr><\/thead><tbody><tr><td><strong>STEP 1 (Semaglutide 2.4 mg)<\/strong><\/td><td>-15.3 kg<\/td><td>-9.4 kg<\/td><td>-5.9 kg<\/td><td><strong>~38%<\/strong><\/td><\/tr><tr><td><strong>SURMOUNT 1 (Tirzepatide 15 mg)<\/strong><\/td><td>-21.6 kg<\/td><td>-16.0 kg<\/td><td>-5.6 kg<\/td><td><strong>~26%<\/strong><\/td><\/tr><tr><td><strong>Standard Caloric Restriction<\/strong><\/td><td>-8.0 kg<\/td><td>-6.0 kg<\/td><td>-2.0 kg<\/td><td><strong>25%\u201335%<\/strong><\/td><\/tr><tr><td><strong>Bariatric Surgery (Gastric Bypass)<\/strong><\/td><td>-35.0 kg<\/td><td>-24.0 kg<\/td><td>-11.0 kg<\/td><td><strong>30%\u201335%<\/strong><\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p class=\"wp-block-paragraph\"><em>Clinical Conclusion:<\/em> Incretin medications do not cause a novel or pathological destruction of lean tissue. The ratio of lean-to-fat loss mirrors the normal physiological response observed in bariatric surgery and conventional calorie-restricted diets.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"is-incretin-induced-muscle-loss-unique\">Is Incretin-Induced Muscle Loss Unique?<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">No. Forbes&#8217; Law of body composition states that when an individual loses body weight, the proportion of lean tissue lost is inversely related to their initial fat mass. Individuals with higher initial adiposity lose a higher percentage of fat and a lower percentage of lean tissue.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">However, GLP-1 medications create two unique behavioral risk factors that can exacerbate muscle wasting if unmanaged:<\/p>\n\n\n\n<ol class=\"wp-block-list\"><li><strong>Severe Hypophagia (Appetite Blunting):<\/strong> Patients frequently reduce their caloric intake by 35% to 50%. In doing so, their absolute protein intake often drops below 0.6 g\/kg\/day, well below the minimum threshold required to stimulate muscle protein synthesis (MPS).<\/li><li><strong>Physical Inactivity and Fatigue:<\/strong> During the initial weeks of therapy, transient fatigue, nausea, and low circulating glucose levels can discourage physical exertion and structured resistance training.<\/li><\/ol>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"risks-sarcopenic-obesity-and-metabolic-consequences\">Risks: Sarcopenic Obesity and Metabolic Consequences<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">While reducing adipose tissue provides profound cardiovascular and metabolic benefits, preserving skeletal muscle is vital for long-term health:<\/p>\n\n\n\n<ul class=\"wp-block-list\"><li><strong>Resting Metabolic Rate (RMR):<\/strong> Skeletal muscle is metabolically active, accounting for roughly 20% of basal daily energy expenditure (approximately 13 kcal\/kg\/day vs 4.5 kcal\/kg\/day for adipose tissue). Preserving muscle helps counteract the adaptive metabolic slowdown that promotes weight regain.<\/li><li><strong>Glucose Clearance:<\/strong> Skeletal muscle is responsible for over <strong>80% of postprandial glucose disposal<\/strong> via insulin-stimulated GLUT4 translocation. Losing significant muscle mass reduces the body&#8217;s largest sink for glucose storage, impairing long-term glycemic resilience.<\/li><li><strong>Functional Sarcopenia:<\/strong> In elderly adults (&gt;65 years), loss of muscle strength (dynapenia) increases the risk of osteopenia, falls, fractures, and functional disability.<\/li><\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"nutritional-strategies-protein-timing-and-leucine-thresholds\">Nutritional Strategies: Protein Timing and Leucine Thresholds<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">To counteract muscle protein breakdown during rapid incretin-mediated weight loss, targeted dietary protocols are essential:<\/p>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"1-elevated-daily-protein-target\">1. Elevated Daily Protein Target<\/h3>\n\n\n\n<ul class=\"wp-block-list\"><li><strong>Recommended Range:<\/strong> <strong>1.2 to 1.6 grams of protein per kilogram of ideal\/adjusted body weight<\/strong> per day (compared to the standard RDA of 0.8 g\/kg).<\/li><li>In individuals engaging in intensive resistance training, targets of <strong>1.6 to 2.0 g\/kg<\/strong> may be appropriate.<\/li><\/ul>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"2-per-meal-leucine-threshold\">2. Per-Meal Leucine Threshold<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">Muscle protein synthesis (MPS) operates on a &#8220;threshold&#8221; model triggered by the essential branched-chain amino acid <strong>leucine<\/strong>:<\/p>\n\n\n\n<ul class=\"wp-block-list\"><li>Each meal should contain at least <strong>2.5 to 3.0 grams of leucine<\/strong> (typically found in 25\u201335 grams of high-quality complete protein such as whey, eggs, chicken, fish, or fortified soy).<\/li><li>Spacing protein intake across 3 to 4 distinct feeding windows throughout the day produces superior 24-hour muscle protein synthesis compared to consuming all protein in a single large evening meal.<\/li><\/ul>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"3-protein-shakes-for-satiated-patients\">3. Protein Shakes for Satiated Patients<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">Because GLP-1 medications produce intense satiety, consuming solid protein can be challenging. Liquid whey protein isolate or plant protein blends provide easily digestible, high-concentration amino acids that bypass prolonged gastric residence.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"exercise-protocols-resistance-training-vs-aerobic-exercise\">Exercise Protocols: Resistance Training vs Aerobic Exercise<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">Exercise type dictates whether the body preserves or catabolizes skeletal muscle during a caloric deficit:<\/p>\n\n\n\n<pre class=\"wp-block-preformatted nm-diagram\">Caloric Deficit Alone:             Caloric Deficit + Resistance Training:\nFat Loss (~70%) + Lean Loss (~30%)  Fat Loss (~90%) + Lean Preservation (~95-100%)<\/pre>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"progressive-resistance-training-the-anchor\">Progressive Resistance Training (The Anchor)<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">Resistance training is the most powerful non-pharmacological stimulus to preserve muscle protein synthesis:<\/p>\n\n\n\n<ul class=\"wp-block-list\"><li><strong>Frequency:<\/strong> 2 to 4 sessions weekly.<\/li><li><strong>Protocol:<\/strong> Focus on compound, multi-joint movements (squats, deadlifts, presses, rows, lunges) targeting major muscle groups.<\/li><li><strong>Intensity:<\/strong> 6 to 12 repetitions per set at 70% to 85% of one-repetition maximum (1RM), taken within 1 to 3 repetitions of mechanical muscular failure.<\/li><\/ul>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"aerobic-conditioning-cardiovascular-support\">Aerobic Conditioning (Cardiovascular Support)<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">While aerobic exercise (walking, cycling, swimming) provides vital cardiorespiratory conditioning, excessive endurance volume without concurrent resistance training can accelerate muscle catabolism during severe energy restriction. Low-impact zone 2 walking (7,000\u201310,000 steps daily) is ideal to maintain energy flux without impairing muscle recovery.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"clinical-monitoring-dexa-scans-and-handgrip-dynamometry\">Clinical Monitoring: DEXA Scans and Handgrip Dynamometry<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">Clinicians monitoring patients on long-term incretin therapy should incorporate objective physical function and body composition assessments:<\/p>\n\n\n\n<ol class=\"wp-block-list\"><li><strong>Serial DEXA Body Composition Scans:<\/strong> Performed at baseline and every 6 to 12 months to quantify absolute changes in fat mass, appendicular lean mass (ALM), and bone mineral density (BMD).<\/li><li><strong>Handgrip Dynamometry:<\/strong> A rapid, validated surrogate measure of overall systemic muscle strength and functional vitality. A decline in handgrip strength during treatment signals inadequate dietary protein or excessive catabolism.<\/li><li><strong>Physical Performance Battery:<\/strong> Sit-to-stand tests (5 times sit-to-stand) and gait speed assessments to identify functional mobility impairments early, particularly in older patients.<\/li><\/ol>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"frequently-asked-questions\">Frequently Asked Questions<\/h2>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"does-mounjaro-cause-less-muscle-loss-than-wegovy\">Does Mounjaro cause less muscle loss than Wegovy?<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">In sub-study data, tirzepatide 15 mg (SURMOUNT-1) showed lean mass loss representing approximately 26% of total weight lost, compared to roughly 38% with semaglutide 2.4 mg (STEP-1). However, these studies were not direct head-to-head comparisons, used slightly different cohorts, and had differing absolute weight loss numbers. Both medications demonstrate acceptable, physiological body composition profiles.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"can-supplements-like-creatine-prevent-muscle-loss-on-glp-1s\">Can supplements like creatine prevent muscle loss on GLP-1s?<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">Creatine monohydrate (3\u20135 grams daily) increases intracellular phosphocreatine stores, supports cellular hydration, and enhances training capacity in resistance exercises. It is a well-tolerated, evidence-backed adjunct to help preserve muscle function during caloric restriction.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"should-i-stop-taking-glp-1s-if-my-dexa-scan-shows-lean-mass-loss\">Should I stop taking GLP-1s if my DEXA scan shows lean mass loss?<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">Not necessarily. Losing some lean tissue is an inevitable biological component of losing significant body mass (carrying 30 kg less body weight requires less blood volume, less water, and less structural connective tissue). Only if functional muscle strength declines or lean loss exceeds 40\u201345% of total loss should clinicians adjust the caloric target, protein intake, or drug dose.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Related reading: <a href=\"https:\/\/novameds.health\/ca\/knowledge-hub\/semaglutide-vs-tirzepatide\/\">Semaglutide vs Tirzepatide: Understanding the Differences<\/a> \u00b7 <a href=\"https:\/\/novameds.health\/ca\/knowledge-hub\/glp-1-side-effects-management\/\">Managing GLP-1 Side Effects: Nausea, Constipation and GI Tolerability<\/a> \u00b7 <a href=\"https:\/\/novameds.health\/ca\/knowledge-hub\/what-happens-when-stopping-glp1\/\">What Happens When Stopping GLP-1 Medicines? Evidence on Weight Regain<\/a> \u00b7 <a href=\"https:\/\/novameds.health\/ca\/knowledge-hub\/tirzepatide-dosage-guide\/\">Tirzepatide Dosage Guide: Titration Schedules and Administration<\/a><\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"references\">Scientific references<\/h2>\n\n\n\n<ol class=\"nm-refs\"><li id=\"ref-1\"><strong>Wilding JPH, et al.<\/strong> <em>Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1 DEXA Sub-study).<\/em> New England Journal of Medicine. 2021;384(11):989-1002. <a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/33567185\/\">PubMed PMID: 33567185<\/a><\/li><li id=\"ref-2\"><strong>Heymsfield SB, et al.<\/strong> <em>Semaglutide 2.4 mg once weekly and body composition in adults with overweight or obesity: STEP 1 body composition sub-study.<\/em> Diabetes, Obesity and Metabolism. 2022;24(12):2400-2410.<\/li><li id=\"ref-3\"><strong>Jastreboff AM, et al.<\/strong> <em>Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1 Body Composition).<\/em> New England Journal of Medicine. 2022;387(3):205-216. <a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/35658024\/\">PubMed PMID: 35658024<\/a><\/li><li id=\"ref-4\"><strong>Forbes GB.<\/strong> <em>Lean body mass-body fat interrelationships in humans.<\/em> Nutrition Reviews. 1987;45(8):225-231. <a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/3306482\/\">PubMed PMID: 3306482<\/a><\/li><li id=\"ref-5\"><strong>Morton RW, et al.<\/strong> <em>A systematic review, meta-analysis and meta-regression of the effect of protein supplementation on resistance training-induced gains in muscle mass and strength in healthy adults.<\/em> British Journal of Sports Medicine. 2018;52(6):376-384. <a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/28698222\/\">PubMed PMID: 28698222<\/a><\/li><\/ol>\n\n\n\n<p class=\"nm-article-note wp-block-paragraph\">This article is educational and does not constitute personalized treatment advice. Treatment decisions depend on individual circumstances and professional assessment.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>When losing significant weight on GLP-1 medicines, between 20% and 40% of total mass lost is lean tissue. We examine clinical trial DEXA findings and evidence-based protocols to preserve skeletal muscle.<\/p>\n","protected":false},"author":0,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[183],"tags":[175,176],"class_list":["post-300","post","type-post","status-publish","format-standard","hentry","category-research","tag-semaglutide","tag-tirzepatide"],"_links":{"self":[{"href":"https:\/\/novameds.health\/ca\/wp-json\/wp\/v2\/posts\/300","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/novameds.health\/ca\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/novameds.health\/ca\/wp-json\/wp\/v2\/types\/post"}],"replies":[{"embeddable":true,"href":"https:\/\/novameds.health\/ca\/wp-json\/wp\/v2\/comments?post=300"}],"version-history":[{"count":3,"href":"https:\/\/novameds.health\/ca\/wp-json\/wp\/v2\/posts\/300\/revisions"}],"predecessor-version":[{"id":430,"href":"https:\/\/novameds.health\/ca\/wp-json\/wp\/v2\/posts\/300\/revisions\/430"}],"wp:attachment":[{"href":"https:\/\/novameds.health\/ca\/wp-json\/wp\/v2\/media?parent=300"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/novameds.health\/ca\/wp-json\/wp\/v2\/categories?post=300"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/novameds.health\/ca\/wp-json\/wp\/v2\/tags?post=300"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}